Gilead Sciences, Inc.
GILD
$114.43
-$2.78-2.37%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 6.04% | 3.32% | 1.54% | 1.50% | -0.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.04% | 3.32% | 1.54% | 1.50% | -0.61% |
| Cost of Revenue | 3.85% | 8.22% | 11.32% | 9.51% | 6.40% |
| Gross Profit | 6.66% | 2.00% | -1.00% | -0.61% | -2.44% |
| SG&A Expenses | -1.01% | -12.03% | -12.11% | 3.33% | 6.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.45% | -2.96% | 0.14% | 7.40% | 9.35% |
| Operating Income | 14.85% | 15.74% | 4.04% | -8.17% | -15.40% |
| Income Before Tax | -89.93% | -97.55% | -79.06% | -85.21% | 17.99% |
| Income Tax Expenses | -83.09% | -95.53% | -73.49% | -64.29% | 0.00% |
| Earnings from Continuing Operations | -91.45% | -98.04% | -81.02% | -91.73% | 22.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -74.47% | -52.38% | -42.22% | 100.00% |
| Net Income | -91.53% | -97.86% | -80.80% | -91.33% | 23.34% |
| EBIT | 14.85% | 15.74% | 4.04% | -8.17% | -15.40% |
| EBITDA | 12.13% | 14.30% | 6.40% | -2.50% | -8.41% |
| EPS Basic | -91.54% | -97.87% | -80.78% | -91.37% | 23.94% |
| Normalized Basic EPS | 13.47% | 15.33% | 4.78% | -6.85% | -13.00% |
| EPS Diluted | -92.09% | -98.39% | -81.49% | -92.21% | 23.16% |
| Normalized Diluted EPS | 13.84% | 15.86% | 5.13% | -6.70% | -13.18% |
| Average Basic Shares Outstanding | -0.08% | -0.16% | -0.28% | -0.38% | -0.50% |
| Average Diluted Shares Outstanding | -0.42% | -0.63% | -0.65% | -0.55% | -0.30% |
| Dividend Per Share | 2.67% | 2.68% | 2.70% | 2.72% | 2.74% |
| Payout Ratio | 11.14% | 46.95% | 4.35% | 10.83% | -0.17% |
